Trade Cytori Therapeutics - PSTV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.38 |
Open* | 0.38 |
1-Year Change* | -60% |
Day's Range* | 0.37 - 0.38 |
52 wk Range | 0.25-1.20 |
Average Volume (10 days) | 253.72K |
Average Volume (3 months) | 6.61M |
Market Cap | 9.48M |
P/E Ratio | -100.00K |
Shares Outstanding | 35.42M |
Revenue | 224.00K |
EPS | -0.79 |
Dividend (Yield %) | N/A |
Beta | 0.40 |
Next Earnings Date | Apr 19, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 23, 2023 | 0.37 | -0.01 | -2.63% | 0.38 | 0.38 | 0.37 |
Feb 22, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Feb 8, 2023 | 0.37 | -0.01 | -2.63% | 0.38 | 0.38 | 0.37 |
Feb 6, 2023 | 0.38 | -0.01 | -2.56% | 0.39 | 0.39 | 0.38 |
Feb 3, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.39 | 0.39 |
Feb 2, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.40 | 0.38 |
Feb 1, 2023 | 0.38 | -0.04 | -9.52% | 0.42 | 0.42 | 0.38 |
Jan 31, 2023 | 0.40 | -0.02 | -4.76% | 0.42 | 0.42 | 0.39 |
Jan 30, 2023 | 0.43 | 0.01 | 2.38% | 0.42 | 0.44 | 0.42 |
Jan 27, 2023 | 0.42 | 0.01 | 2.44% | 0.41 | 0.42 | 0.40 |
Jan 26, 2023 | 0.41 | 0.00 | 0.00% | 0.41 | 0.42 | 0.41 |
Jan 25, 2023 | 0.41 | 0.01 | 2.50% | 0.40 | 0.42 | 0.40 |
Jan 24, 2023 | 0.41 | 0.00 | 0.00% | 0.41 | 0.41 | 0.41 |
Jan 23, 2023 | 0.41 | -0.01 | -2.38% | 0.42 | 0.43 | 0.41 |
Jan 20, 2023 | 0.41 | -0.01 | -2.38% | 0.42 | 0.43 | 0.40 |
Jan 19, 2023 | 0.42 | 0.01 | 2.44% | 0.41 | 0.42 | 0.40 |
Jan 18, 2023 | 0.42 | -0.03 | -6.67% | 0.45 | 0.45 | 0.40 |
Jan 17, 2023 | 0.45 | 0.00 | 0.00% | 0.45 | 0.45 | 0.43 |
Jan 13, 2023 | 0.45 | 0.07 | 18.42% | 0.38 | 0.45 | 0.38 |
Jan 9, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Cytori Therapeutics Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0.224 | 0 | 0.303 | 6.998 | 6.654 |
Revenue | 0.224 | 0 | 0.303 | 6.998 | 6.654 |
Cost of Revenue, Total | 2.373 | ||||
Gross Profit | 4.281 | ||||
Total Operating Expense | 19.936 | 12.492 | 9.887 | 10.655 | 19.352 |
Selling/General/Admin. Expenses, Total | 10.238 | 6.853 | 6.406 | 5.29 | 8.357 |
Research & Development | 9.698 | 5.323 | 2.7 | 5.365 | 8.622 |
Interest Expense (Income) - Net Operating | |||||
Unusual Expense (Income) | 0 | 0.316 | 0.781 | 0 | |
Operating Income | -19.712 | -12.492 | -9.584 | -3.657 | -12.698 |
Interest Income (Expense), Net Non-Operating | -0.563 | -0.907 | 1.343 | 1.607 | 0.354 |
Other, Net | 0 | -1.233 | -0.29 | ||
Net Income Before Taxes | -20.275 | -13.399 | -8.241 | -3.283 | -12.634 |
Net Income After Taxes | -20.275 | -13.399 | -8.241 | -3.283 | -12.634 |
Net Income Before Extra. Items | -20.275 | -13.399 | -8.241 | -3.283 | -12.634 |
Net Income | -20.275 | -13.399 | -8.241 | -10.887 | -12.634 |
Total Adjustments to Net Income | 0 | -0.554 | -2.487 | ||
Income Available to Common Excl. Extra. Items | -20.275 | -13.399 | -8.241 | -3.837 | -15.121 |
Income Available to Common Incl. Extra. Items | -20.275 | -13.399 | -8.241 | -11.441 | -15.121 |
Diluted Net Income | -20.275 | -13.399 | -8.241 | -11.441 | -15.121 |
Diluted Weighted Average Shares | 26.2553 | 12.0892 | 4.42784 | 1.38401 | 0.17385 |
Diluted EPS Excluding Extraordinary Items | -0.77223 | -1.10835 | -1.86118 | -2.77237 | -86.9768 |
Diluted Normalized EPS | -0.77223 | -1.08221 | -1.6848 | -2.77237 | -86.9768 |
Total Extraordinary Items | 0 | -7.604 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 0.151 | 0.073 | 0 | 0 | 0 |
Revenue | 0.151 | 0.073 | 0 | ||
Total Operating Expense | 5.723 | 5.167 | 5.12 | 3.926 | 3.939 |
Selling/General/Admin. Expenses, Total | 3.585 | 2.222 | 2.289 | 2.141 | 2.042 |
Research & Development | 2.138 | 2.945 | 2.831 | 1.785 | 1.599 |
Operating Income | -5.572 | -5.094 | -5.12 | -3.926 | -3.939 |
Interest Income (Expense), Net Non-Operating | -0.086 | -0.125 | -0.162 | -0.19 | -0.216 |
Net Income Before Taxes | -5.658 | -5.219 | -5.282 | -4.116 | -4.155 |
Net Income After Taxes | -5.658 | -5.219 | -5.282 | -4.116 | -4.155 |
Net Income Before Extra. Items | -5.658 | -5.219 | -5.282 | -4.116 | -4.155 |
Net Income | -5.658 | -5.219 | -5.282 | -4.116 | -4.155 |
Income Available to Common Excl. Extra. Items | -5.658 | -5.219 | -5.282 | -4.116 | -4.155 |
Income Available to Common Incl. Extra. Items | -5.658 | -5.219 | -5.282 | -4.116 | -4.155 |
Diluted Net Income | -5.658 | -5.219 | -5.282 | -4.116 | -4.155 |
Diluted Weighted Average Shares | 33.6534 | 27.4417 | 22.2548 | 21.5071 | 15.4729 |
Diluted EPS Excluding Extraordinary Items | -0.16813 | -0.19019 | -0.23734 | -0.19138 | -0.26853 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Diluted Normalized EPS | -0.16813 | -0.19019 | -0.23734 | -0.19138 | -0.24927 |
Unusual Expense (Income) | 0 | 0 | 0.298 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 19.724 | 9.175 | 19.825 | 9.648 | 14.864 |
Cash and Short Term Investments | 18.4 | 8.346 | 17.552 | 5.261 | 9.55 |
Cash & Equivalents | 18.4 | 8.346 | 17.552 | 5.261 | 9.55 |
Total Receivables, Net | 0 | 1.313 | 0.178 | 0.145 | |
Accounts Receivable - Trade, Net | 0 | 1.169 | 0.178 | 0.145 | |
Total Inventory | 0 | 0.107 | 0.107 | 3.183 | |
Other Current Assets, Total | 0.007 | 0.059 | 0.04 | 4.102 | 1.986 |
Total Assets | 21.981 | 12.105 | 23.229 | 23.991 | 31.615 |
Property/Plant/Equipment, Total - Net | 1.818 | 2.456 | 2.96 | 2.299 | 3.052 |
Goodwill, Net | 0.372 | 0.372 | 0.372 | 0.372 | 3.922 |
Intangibles, Net | 0.051 | 0.086 | 7.207 | ||
Other Long Term Assets, Total | 0.016 | 0.016 | 0.072 | 11.672 | 2.57 |
Total Current Liabilities | 5.87 | 8.539 | 14.486 | 17.559 | 18.414 |
Payable/Accrued | 0.245 | 2.777 | 4.79 | ||
Notes Payable/Short Term Debt | 1.608 | 6.335 | 0 | 14.202 | 13.624 |
Current Port. of LT Debt/Capital Leases | 0 | 0.01 | 11.18 | ||
Total Liabilities | 11.145 | 9.074 | 22.069 | 18.766 | 18.615 |
Total Long Term Debt | 5.005 | 0 | 0.008 | 0 | 0 |
Long Term Debt | 5.005 | 0 | |||
Other Liabilities, Total | 0.27 | 0.535 | 7.575 | 1.207 | 0.201 |
Total Equity | 10.836 | 3.031 | 1.16 | 5.225 | 13 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.016 | 0.007 | 0.004 | 0 | 0.058 |
Additional Paid-In Capital | 457.73 | 436.535 | 426.426 | 418.39 | 413.304 |
Retained Earnings (Accumulated Deficit) | -446.91 | -433.511 | -425.27 | -414.383 | -401.749 |
Other Equity, Total | 0 | 1.218 | 1.387 | ||
Total Liabilities & Shareholders’ Equity | 21.981 | 12.105 | 23.229 | 23.991 | 31.615 |
Total Common Shares Outstanding | 15.51 | 6.74903 | 3.88059 | 0.29661 | 0.11565 |
Property/Plant/Equipment, Total - Gross | 3.233 | 3.843 | 3.981 | 0 | |
Accrued Expenses | 1.529 | 1.137 | 2.973 | 0 | |
Other Current Liabilities, Total | 0.122 | 0.023 | 0.006 | 0.58 | |
Prepaid Expenses | 1.317 | 0.77 | 0.813 | ||
Accumulated Depreciation, Total | -1.415 | -1.387 | -1.021 | ||
Accounts Payable | 2.611 | 0.789 | 0.327 | ||
Capital Lease Obligations | 0 | 0.008 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 22.104 | 19.724 | 22.097 | 18.001 | 15.446 |
Cash and Short Term Investments | 21.239 | 18.4 | 21.28 | 17.161 | 14.447 |
Cash & Equivalents | 21.239 | 18.4 | 21.28 | 17.161 | 14.447 |
Other Current Assets, Total | 0.865 | 1.324 | 0.817 | 0.84 | 0.999 |
Total Assets | 24.516 | 21.981 | 24.75 | 20.834 | 18.336 |
Property/Plant/Equipment, Total - Net | 1.874 | 1.818 | 2.205 | 2.376 | 2.425 |
Goodwill, Net | 0.372 | 0.372 | 0.372 | 0.372 | 0.372 |
Intangibles, Net | 0.15 | 0.051 | 0.06 | 0.069 | 0.077 |
Other Long Term Assets, Total | 0.016 | 0.016 | 0.016 | 0.016 | 0.016 |
Total Current Liabilities | 4.921 | 5.87 | 9.488 | 8.354 | 8.315 |
Payable/Accrued | 3.203 | 4.151 | 2.63 | 1.609 | 1.713 |
Accrued Expenses | 0.11 | 0.111 | 0.106 | 0.127 | 0.113 |
Notes Payable/Short Term Debt | 1.608 | 1.608 | 6.752 | 6.618 | 6.486 |
Current Port. of LT Debt/Capital Leases | 0 | 0.003 | |||
Total Liabilities | 9.874 | 11.145 | 9.995 | 8.889 | 8.823 |
Total Long Term Debt | 4.718 | 5.005 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | ||||
Other Liabilities, Total | 0.235 | 0.27 | 0.507 | 0.535 | 0.508 |
Total Equity | 14.642 | 10.836 | 14.755 | 11.945 | 9.513 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.022 | 0.016 | 0.015 | 0.012 | 0.01 |
Additional Paid-In Capital | 465.646 | 457.73 | 457.495 | 450.964 | 445.734 |
Retained Earnings (Accumulated Deficit) | -451.026 | -446.91 | -442.755 | -439.031 | -436.231 |
Total Liabilities & Shareholders’ Equity | 24.516 | 21.981 | 24.75 | 20.834 | 18.336 |
Total Common Shares Outstanding | 22.1976 | 15.51 | 15.36 | 12.0875 | 10.1805 |
Long Term Debt | 4.718 | 5.005 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.399 | -8.241 | -10.887 | -12.634 | -22.686 |
Cash From Operating Activities | -10.28 | -8.434 | -5.906 | -11.975 | -18.128 |
Cash From Operating Activities | 0.395 | 0.366 | 0.896 | 2.004 | 2.151 |
Non-Cash Items | 1.486 | -0.678 | 5.023 | -0.313 | 3.444 |
Cash Interest Paid | 0.388 | 0.567 | 1.188 | 1.331 | 1.364 |
Changes in Working Capital | 1.238 | 0.119 | -0.938 | -1.032 | -1.037 |
Cash From Investing Activities | -0.082 | -0.493 | 5.57 | -0.133 | -1.383 |
Capital Expenditures | -0.144 | -0.493 | -0.067 | -0.133 | -1.496 |
Other Investing Cash Flow Items, Total | 0.062 | 0 | 5.637 | 0 | 0.113 |
Cash From Financing Activities | 20.416 | -0.319 | 12.631 | 7.168 | 16.815 |
Financing Cash Flow Items | 0 | -1.598 | -2.078 | ||
Total Cash Dividends Paid | |||||
Issuance (Retirement) of Stock, Net | 20.692 | 5.105 | 16.454 | 8.766 | 23.613 |
Issuance (Retirement) of Debt, Net | -0.276 | -5.424 | -3.823 | 0 | -4.72 |
Foreign Exchange Effects | 0 | -0.004 | 0.016 | 0.011 | |
Net Change in Cash | 10.054 | -9.246 | 12.291 | -4.924 | -2.685 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.116 | -13.399 | -9.244 | -5.52 | -2.72 |
Cash From Operating Activities | -3.876 | -10.28 | -7.656 | -5.405 | -3.006 |
Cash From Operating Activities | 0.147 | 0.395 | 0.266 | 0.179 | 0.088 |
Non-Cash Items | 0.284 | 1.486 | 0.892 | 0.53 | 0.257 |
Cash Interest Paid | 0.087 | 0.388 | 0.292 | 0.29 | 0.096 |
Changes in Working Capital | -0.191 | 1.238 | 0.43 | -0.594 | -0.631 |
Cash From Investing Activities | -0.577 | -0.082 | -0.084 | -0.08 | -0.084 |
Capital Expenditures | -0.327 | -0.144 | -0.134 | -0.08 | -0.084 |
Cash From Financing Activities | 7.292 | 20.416 | 20.674 | 14.3 | 9.191 |
Issuance (Retirement) of Stock, Net | 7.694 | 20.692 | 20.682 | 14.308 | 9.197 |
Issuance (Retirement) of Debt, Net | -0.402 | -0.276 | -0.008 | -0.008 | -0.006 |
Net Change in Cash | 2.839 | 10.054 | 12.934 | 8.815 | 6.101 |
Other Investing Cash Flow Items, Total | -0.25 | 0.062 | 0.05 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.0859 | 1092953 | 385 | 2022-12-31 | LOW |
Parkman Healthcare Partners LLC | Hedge Fund | 1.6474 | 583467 | -741558 | 2022-12-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7286 | 258052 | -385 | 2022-12-31 | LOW |
Schonfeld Strategic Advisors LLC | Hedge Fund | 0.5376 | 190400 | 190400 | 2022-12-31 | HIGH |
Millennium Management LLC | Hedge Fund | 0.3865 | 136903 | 124500 | 2022-12-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2948 | 104427 | 0 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.2376 | 84147 | -22260 | 2022-12-31 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 0.2213 | 78370 | 7470 | 2022-12-31 | HIGH |
Petersen (Gregory B) | Individual Investor | 0.1765 | 62500 | 0 | 2023-02-23 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.0972 | 34414 | 0 | 2022-12-31 | LOW |
Great Valley Advisor Group, Inc. | Investment Advisor | 0.0949 | 33600 | 0 | 2022-12-31 | MED |
Hedrick (Marc H) | Individual Investor | 0.0948 | 33580 | 0 | 2023-02-23 | LOW |
Creative Planning, Inc. | Investment Advisor/Hedge Fund | 0.0947 | 33539 | 0 | 2022-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0906 | 32089 | 0 | 2022-12-31 | LOW |
B. Riley Wealth Advisors, Inc. | Investment Advisor | 0.0706 | 25001 | 25001 | 2022-12-31 | MED |
UBS Financial Services, Inc. | Investment Advisor | 0.0537 | 19003 | 2795 | 2022-12-31 | LOW |
Clowes (Howard) | Individual Investor | 0.0508 | 18000 | 0 | 2023-02-23 | MED |
Virtu Americas LLC | Research Firm | 0.0385 | 13647 | 13647 | 2022-12-31 | HIGH |
Sims Andrew (John Hugh MacIntyre) | Individual Investor | 0.0345 | 12230 | 0 | 2023-02-23 | LOW |
Warberg Asset Management LLC | Hedge Fund | 0.0282 | 10000 | 0 | 2022-12-31 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cytori Therapeutics Company profile
About Plus Therapeutics Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Plus Therapeutics Inc revenues decreased from $303K to $0K. Net loss increased 63% to $13.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 97% to $5.2M (expense), Change in fair value of liability instru decrease of 100% to $6K (income).
Equity composition
Common Stock $.001 Par, 02/11, 95M auth., 51,963,679 issd. Insiders own 14.62% IPO:N/A. 05/16, 1-for-15 reverse stock split.
Industry: | Biotechnology & Medical Research (NEC) |
4200 Marathon Blvd Ste 200
78756-3433
Income Statement
- Annual
- Quarterly
News

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com